Earnings ·
Summit Therapeutics reports Q3 net loss of $208M, closes $2B AstraZeneca equity investment
SMMTSummit Therapeutics Inc.
Summit Therapeutics reported a GAAP net loss of $208.4 million for the third quarter ended September 30, 2026, or $0.26 per share, compared to a $231.8 million loss in the prior year period. The company closed its strategic equity investment with AstraZeneca on October 5, receiving $2.0 billion in proceeds. Cash and short-term investments stood at $629.8 million at quarter-end. The filing also confirms that stockholders approved an amendment to increase authorized common shares by 1 billion to 2 billion. Summit Therapeutics is a biopharmaceutical oncology company focused on the development of ivonescimab.